Research Council

The purpose of the Div. 55 Research Council is to promote dissemination of high-quality, evidence-based research related to the causes of and treatments for mental illness and substance use disorders. The task of the council is to keep abreast of the clinical research relevant to the specialty and highlight articles and issues of interest. It encourages the critical reading of research and monitors ongoing trends in clinical psychopharmacology with an informed understanding of the needs of the populations served by psychologists specially trained in clinical psychopharmacology. The Research Council posts relevant recent articles on this website, disseminates relevant information on clinical psychopharmacology to the membership via the Div. 55 listserv, and acts as consultant to Div. 55 and other APA Divisions, and as a potential advisory resource to inform APA policy decisions on matters related to psychologists who have an interest in the application of psychopharmacological principles within their practice or those specially trained psychologists who have or intend to pursue prescription privileges. Finally, the Research Council offers its members’ expertise and knowledge base as speakers on topics related to psychopharmacology and as a resource to SPTA committees in states that are in the process of or contemplating pursuing RxP legislation.

Below you will find a list of current articles and citations that have been reviewed by the council. Members of ASAP/Div. 55 are encouraged to submit articles for inclusion on the listing. Inclusion of an articles or citation in this listing does not indicate support or endorsement of the council for the contents of the article but rather points out articles of interest and worthy of individual review and consideration.

• Clozapine Cardiotoxicity: A Compendium for Psychiatry Clinicians  
• Asmara, K. E., Fèvec, B., Collea, R., Gressiera, F., Vievard, A., Trabadob, S. et al. 2018. Early weight gain predicts later weight gain in depressed patients treated with antidepressants: Findings from the METADAP cohort. Journal of Affective Disorders 241, 22–28.
  
• Benson, K., Woodlief, D.T., Flory, K., Siceloff, E.R., Coleman, K. & Lamont, A. 2018. Is ADHD, Independent of ODD, Associated With Whether and Why College Students Misuse Stimulant Medication? Experimental and Clinical Psychopharmacology, 26, 5, 476–487. http://dx.doi.org/10.1037/pha0000202
  
• Cipriani, A. Furukawa, T.A., Salanti, G., Chaimani, A., Atkinson, L.Z., Ogawa, Y. et al. 2018. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis Lancet, 391, 1357–66 http://dx.doi.org/10.1016/S0140-6736(17)32802-7
• Davies, J. 2018. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addictive Behaviors, https://doi.org/10.1016/j.addbeh.2018.08.027
• Lopez-Leon, S., Lopez-Gomez, M.I., Warner, B. & Ruiter-Lopez, L. Psychotropic medication in children and adolescents in the United States in the year 2004 vs 2014. 2018. DARU Journal of Pharmaceutical Sciences 26, 5–10. https://doi.org/10.1007/s40199-018-0204-6
• Maust, D.T., Kim, H.M., Chiang, C. Kales, H.C. 2018. Association of the Centers for Medicare & Medicaid Services’ National Partnership to Improve Dementia Care With the Use of Antipsychotics and Other Psychotropics in Long-term Care in the United States From 2009 to 2014. JAMA Intern Med.,178, 5, 640-647. doi:10.1001/jamainternmed.2018.0379
• Rheker, J., Rief, W., Doering, B.K. & Winkler, A. 2018. Assessment of Adverse Events in Clinical Drug Trials: Identifying Amitriptyline’s Placebo- and Baseline-Controlled Side Effects. Experimental and Clinical Psychopharmacology, 26, 3, 320–326. http://dx.doi.org/10.1037/pha0000194
• Sharon, G., Sampson,T.R., Geschwind, D.H. & Mazmanian, S.K.. 2016. The Central Nervous System and the Gut Microbiome. Cell, 167, 915-932.
• Streck, J.M., Ochalek, T.A., Badger, G.J. & Sigmon, S.C. 2018. Interim Buprenorphine Treatment During Delays to Comprehensive Treatment: Changes in Psychiatric Symptoms. Experimental and Clinical Psychopharmacology, 26, 4, 403–409. http://dx.doi.org/10.1037/pha0000199
• Zeier, Z. , L.L., Kalin, N.H., Rodriguez, C.I., McDonald, W.M., Widge, A.S., & Nemeroff, C.B. 2018. Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing. Am. J.  Psychiatry, 175, 9, 873-886.